[A23-31] Durvalumab (NSCLC) – Benefit assessment according to §35a Social Code Book V
Last updated 05.10.2023
Project no.:
A23-31
Commission:
Commission awarded on 03.04.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK-positive mutations; first-line treatment
- PD-L1 expression ≥ 50%: added benefit not proven
- PD-L1 expression < 50%: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A18-69 | Durvalumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-87 | Durvalumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-26 | Durvalumab (malignant biliary cystic tumour [BCT]) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-27 | Durvalumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| G23-20 | Tremelimumab and durvalumab (NSCLC) – Second addendum to Project A23-29 | A23-31 | Commission completed |
| A23-84 | Tremelimumab and durvalumab (NSCLC) - Addendum to Commissions A23-29 and A23-31 | Commission completed |
| A23-138 | Durvalumab (HCC) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
05-10-2023 A G-BA decision was published.
G-BA documents on this decision